On October 6, 2026 Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be making an invited keynote presentation entitled "Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer" at the annual UK National Health Service (NHS) CancerCare Oncology Conference on Tuesday, October 6, at 11:30 a.m. UK time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CancerCare Conference brings together NHS leaders and clinicians, cancer alliances and other healthcare professionals from across the UK to discuss developments in cancer care, innovation and emerging treatments.

Dr. Bosch will discuss the new era of cancer vaccines, the need for personalized treatments, the unique capabilities of dendritic cell (DC) based cancer vaccines such as DCVax, clinical trial results, potential combination treatments and related matters. The slide deck will be posted on the Northwest Biotherapeutics website after the NHS conference.

(Press release, Northwest Biotherapeutics, OCT 6, 2026, View Source [SID1234673215])